Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
Top Cited Papers
Open Access
- 1 August 2005
- Vol. 54 (8), 1121-1125
- https://doi.org/10.1136/gut.2004.049460
Abstract
Background: Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions. Aims: The purpose of this meta-analysis was to provide a more precise estimate of the relative risk of lymphoma among IBD patients treated with azathioprine or 6-MP. Methods: Studies were included if they were English language, full article, cohort studies specifically designed to evaluate cancer as an adverse outcome of treatment with azathioprine or 6-MP. Pooled standardised incidence ratios were calculated to estimate the relative risk of lymphoma associated with therapy. Heterogeneity was assessed using Poisson regression. Sensitivity analyses examined the influence of individual studies on risk estimate and heterogeneity statistics. Results: Six studies were identified that met our inclusion criteria. When the data were combined across all studies, the pooled relative risk was 4.18 (95% confidence interval 2.07–7.51; 11 observed cases, 2.63 expected). Sensitivity analysis showed that exclusion of any one study had a relatively small effect on the pooled relative risk estimate (range 3.49–5.21) but excluding either the study with the highest or lowest estimated relative risk eliminated the statistically significant heterogeneity. Conclusions: Our data suggest an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP. The increased risk of lymphoma could be a result of the medications, the severity of the underlying disease, or a combination of the two.Keywords
This publication has 18 references indexed in Scilit:
- Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprineAlimentary Pharmacology & Therapeutics, 2002
- Inflammatory bowel disease is not associated with an increased risk of lymphomaGastroenterology, 2001
- Cancer risk in patients with inflammatory bowel diseaseCancer, 2001
- Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is lowGut, 2000
- Hodgkin's disease risk is increased in patients with ulcerative colitisGastroenterology, 2000
- Incidence of non-hodgkin lymphoma in kidney and heart transplant recipientsThe Lancet, 1993
- Extracolonic malignancies in inflammatory bowel diseaseCancer, 1991
- INCREASED FREQUENCY OF POSTTRANSPLANT LYMPHOMAS IN PATIENTS TREATED WITH CYCLOSPORINE, AZATHIOPRINE, AND PREDNISONETransplantation, 1989
- Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.Annals Of The Rheumatic Diseases, 1988
- Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatmentAmerican Journal Of Medicine, 1985